The vaccine technology mainly focuses on Dengue fever along with other infectious diseases that include Murray River encephalitis and Japanese encephalitis.
Under the agreement BioDiem is provided with the facility to sublicense the technology, payment of patent registration costs and is confirmed Industry royalties.
BioDiem CEO Julie Phillips said the company is delighted to announce the completion of the licensing agreement, that sees BioDiem’s commercial expertise in the area of vaccines fittingly partnered with the exciting research developed by ANU.
”Our focus on infectious diseases is an excellent fit for this new technology which has strong potential as an asset for outlicensing."Julie added.
According to the World Health Organization Dengue fever is a disease caused by a mosquito-borne virus that affects between 50 and 100 million people every year and has no suitable vaccine.